

Register by August 31st and save \$300  
Register by September 30th and save \$200

Building on 18 Years of Expertise in Europe, SMi Presents...

# Superbugs & Superdrugs USA






The Global Attack Against Bacteria's Defensive Walls

CONFERENCE:  
14TH - 15TH  
WORKSHOPS: 16TH  
**NOV**  
**2016**



Renaissance Woodbridge Hotel,  
Iselin, New Jersey, USA

## Key reasons to attend:

-  **CURRENT STATUS:** Receive progressive insight into innovative developments in big pharma with updates on drug discovery
-  **FAST TO MARKET:** Evaluate zoonotic link between animals and humans to target emerging infectious diseases
-  **DRUG DISCOVERY:** Enable antibiotic drug development through novel approaches in treating gram-negative infections
-  **TARGETING MECHANISMS:** Restore antibiotic sensitivity in multi-drug resistance infections
-  **PREPARE:** Prepare for outbreaks with case study insight into new paradigms for prevention and industry collaboration

Learn about progress in the development of National Action Plans with exclusive keynotes from PAHO/WHO, NIAID and BARDA

## Chair:

- William Weiss**, Director, Pre-Clinical Services, UNT Health Science Center

## Expert Speakers include:

- Dr Pilar Ramon-Pardo**, Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, **PAHO/WHO**
- Dr Christopher Houchens**, Branch Chief, Antibacterials Program, **BARDA**
- Dr Rosemarie Aurigemma**, Chief, Biodefense Drug Development Section, DMID, NIAID, **NIH**
- Dr John Rex**, Senior Vice President and Chief Strategy Officer, Infection Business Unit, **AstraZeneca**
- Dr Annaliesa Anderson**, Vice President and CSO Bacterial Vaccines, **Pfizer**
- Dr Anthony Simon Lynch**, Senior Scientific Director, **Janssen Research & Development LLC**
- Dr Mahesh Kumar**, Vice President, Global Biological Research and Development, **Zoetis**

Sponsored by:



PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS  
Wednesday 16th November 2016, Renaissance Woodbridge Hotel, Iselin, New Jersey, USA

### The Use of Animal Models in Pre-Clinical Drug Development

8.30am - 12.30pm

Workshop Leaders:

**William Weiss**, Director, Pre-Clinical Services,  
UNT Health Science Center  
**Mark Pulse**, Associate Director, Pre-Clinical Services,  
UNT Health Science Center

### Opportunities and challenges in development of new antibacterial therapeutics

1.30pm - 5.30pm

Workshop Leaders:

**Dr Tina Guina**, Therapeutics Development Project Officer,  
The National Institute of Allergy and Infectious Diseases  
**Dr Francois Franceschi**, Therapeutics Development Program Officer,  
The National Institute of Allergy and Infectious Diseases

[www.superbugs-usa.com](http://www.superbugs-usa.com)

Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE



@SMIPHARM  
#superbugusa



# Superbugs & Superdrugs USA

Day One | Monday 14th November 2016

8.30 Registration & Coffee

9.00 **Chairman's Opening Remarks**  
**William Weiss**, Director, Pre-Clinical Services,  
UNT Health Science Center

## PUBLIC AND PRIVATE PARTNERSHIPS

### OPENING ADDRESS

9.10 **Global action plan on antimicrobial resistance**

- Strategic lines of action
- Progress in the development of National Action Plans
- Barriers and challenges for implementation of the Global Action Plan
- The way forward

**Dr Pilar Ramon-Pardo**, Advisor on Clinical Management of Infectious Diseases and Antimicrobial Resistance, PAHO/WHO

9.50 **NIAID and National Strategy for CARB**

- NIAID-supported research on antimicrobial drug resistance has helped facilitate translation of basic research discoveries from "bench to bedside".
- The National Strategy for Combating Antibiotic Resistant Bacteria has allowed all facets of this drug discovery/development support to be boosted in order to drive greater interest and encourage investment and innovation.
- NIAID hopes that the investment made will result in an upwelling of novel products into the pipeline and lead to new licensed products to stem the surge of resistant infections.
- This presentation will describe NIAID programs that support antimicrobial product development, the results of the first year of the CARB initiative and the opportunities that lay ahead.

**Dr Rosemarie Aurigemma**, Chief, Biodefense Drug Development Section, DMID, NIAID, NIH

10.30 Morning Coffee

11.00 **BARDA's end-to-end support of antibacterial product development**

- Launching the Biopharmaceutical Accelerator to repopulate the antimicrobial pipeline
- Utilizing innovative public-private partnering mechanisms to stimulate clinical product development
- Expanding the BARDA portfolio to include nontraditional antimicrobials
- BARDA's efforts to address objectives in the US National Action Plan for CARB

**Dr Christopher Houchens**, Branch Chief, Antibacterials Program, BARDA

### KEYNOTE ADDRESS

11.40 **Enabling drug discovery and development to address the crisis of antimicrobial resistance**

- New tools
- New pathways
- Remaining challenges

**Dr John Rex**, Senior Vice President and Chief Strategy Officer, Infection Business Unit, AstraZeneca

12.20 Networking Lunch

## RESEARCH AND DEVELOPMENT UPDATES

1.30 **POL7080 – Polyphor's new class of macrocycle antibiotic**

- POL7080, Murapavadin, is the frontrunner of a new class of novel macrocycle antibiotic discovered and developed by Polyphor
- It is a Pseudomonas-specific antibiotic, highly active on a broad panel of clinical isolates, including multi-drug resistant (MDR) strains and colistin-resistant isolates.
- Phase I clinical trial in healthy volunteers in Europe demonstrated the clinical safety and tolerability of POL7080 and a Phase II study is on-going in ventilator-associated pneumonia (VAP)
- Polyphor is developing a novel class of broad-spectrum Gram-negative antibiotics derived from our macrocycle technology platform

**Dr Daniel Obrecht**, Chief Scientific Officer,  
Polyphor



### KEYNOTE ADDRESS

2.10 **Progress towards developing vaccines for the prevention of Staphylococcus aureus infections**

- Staphylococcus aureus causes serious infections in healthcare settings
- Antibiotic resistance make infections harder to treat and non-antibiotic prophylactic approaches could address this unmet medical need
- Approaches to design and develop vaccines for the prevention of S. aureus infections will be discussed

**Dr Annaliesa Anderson**, Vice President and CSO Bacterial Vaccines, Pfizer

2.50 **Innovative approaches to treating gram-negative infections**

- Turning gram-positive antibiotics into gram-negative therapeutics
- The concept of potentiation
- Proof of concept with generic Gram-positive agents

**Dr Scott Coleman**, Head of Nonclinical Development, Spero Therapeutics

3.30 Afternoon Tea

4.00 **Microbial metagenomics-based antibiotic discovery**

- Accessing the biosynthetic output of overlooked unculturable microbes for new medicines
- Surveying natural variants of known secondary metabolites for improved biological and pharmaceutical properties
- Synthetic biological manipulation of biosynthetic gene clusters as a method of lead optimization

**Dr David Pompliano**, Co-Founder and CSO, Lodo Therapeutics

4.40 **Targeting mechanisms of resistance using protein resistance neutralizers**

- Restoring antibiotic sensitivity in multi-drug resistance infections
- Direct targeting of resistance gene products using protein "resistance neutralizers"
- Enhance antibiotic effects, expand efficacy and maintain clinical usefulness

**Dr David Cook**, Chief Scientific Officer,  
Blueberry Therapeutics Ltd

EUROPEAN VIEW

5.20 **Chairman's Closing Remarks and Close of Day One**

Register online at [www.superbugs-usa.com](http://www.superbugs-usa.com)

Sponsored by:



**Noigel LLC** was established in 2010 by a group of scientists as the biopharmaceutical startup company to study and develop drugs based on principle multiple synergisms, based on TRIZ and modern Design and Technologies in different fields: anticancer, antiviral, antimicrobial drugs with new properties. [www.noigel.eu](http://www.noigel.eu)



**Polyphor** is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Macrocycles represent a new drug class complementary to the traditional small molecules and large biopharmaceuticals. Polyphor leverages its unique and proprietary technology platforms to develop its own product portfolio and to pursue licensing and collaboration opportunities with industry partners. The company's lead drug candidates include POL6326, Balixafortide, (Phase Ib), a CXCR4 antagonist, for stem cell transplantation, tissue repair and combination treatments in oncology; POL7080, Murepavadin, (Phase II), a highly specific antibiotic with a novel mode-of-action to treat Pseudomonas infections; and POL6014 (Phase Ib), an inhaled inhibitor of neutrophil elastase for the treatment of CF and other lung diseases. Polyphor is a privately held company with about 100 employees, headquartered in Allschwil, near Basel. [www.polyphor.com](http://www.polyphor.com)

SPONSORSHIP AND EXHIBITION OPPORTUNITIES

SMI offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

# Superbugs & Superdrugs USA

Day Two | Tuesday 15th November 2016

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks

**William Weiss**, Director, Pre-Clinical Services,  
UNT Health Science Center

## OPENING KEYNOTE ADDRESS

9.10 First to know and fast to market

- Infectious diseases between animals and people
- First to know and fast to market
- Making a difference

**Dr Mahesh Kumar**, Vice President, Global Biological Research and Development, **Zoetis**

## NOVEL ANTIBACTERIAL THERAPEUTIC APPROACHES

### KEYNOTE ADDRESS

9.50 Novel protein-based biologics for the treatment and prevention of serious bacterial infections

- Bacteriophage-derived lysins, antibody-drug conjugates and novel protein scaffolds
- Challenges in discovery and development
- Potential for clinical utility as stand-alone agents or as adjuncts to existing therapies

**Dr Anthony Simon Lynch**, Senior Scientific Director, **Janssen Research & Development LLC**

10.30 Morning Coffee

11.00 Antimicrobial combination therapy: Use and misuse

- Rationale for the use of antibiotic combinations
- Advantages / disadvantages of combining antimicrobial agents
- Currently used antibiotic combinations
- Novel and non-traditional antimicrobial combinations

**William Weiss**, Director, Pre-Clinical Services,  
UNT Health Science Center

11.40 The novel strategy to fight multidrug resistance by multiple drugs synergism, based on docking in drug design and TRIZ

- The novel strategy to fight multidrug resistance
- Multiple drugs synergism in view of multidrug resistance
- The novel strategy to decrease antibiotics toxicity

**Dr Boris Farber**, CEO, **Noigel, LLC**



12.20 Networking Lunch

1.30 What can be done in order to be successful?

EUROPEAN VIEW

- Novel approaches and compounds
- New scenarios in innovation
- Rational health system

**Dr Domingo Gargallo-Viola**, Co-Founder and CSO,  
**ABAC Therapeutics**

## STRENGTHENING THE PIPELINE

2.10 Addressing the evolving challenge of  $\beta$ -lactamase mediated antimicrobial resistance: ETX2514, a next-generation BLI with potent broad spectrum activity against Class A, C and D enzymes

- ETX2514 is a novel diazabicyclooctenone with potent, broad spectrum inhibitory activity against Class A, C and D serine  $\beta$ -lactamases
- ETX2514 restores the antimicrobial activity of a variety of  $\beta$ -lactams against multi-drug resistant Gram-negative pathogens
- The combination of ETX2514 and sulbactam is highly effective in vitro and in vivo against clinical MDR and XDR *A. baumannii*

**Dr Alita Miller**, Head of Bioscience, **Entasis Therapeutics**

2.50 Afternoon Tea

3.20 Novel beta-lactamase inhibitors to calm the carbapenemase storm

- Vaborbactam, the first cyclic boronic acid beta-lactamase inhibitor to enter clinical development
- Overview of Meropenem-vaborbactam Ph 3 clinical program
- Beta-lactamase inhibitors with activity against both serine and metallo-beta-lactamases
- Overview of microbiological activity

**Dr Olga Lomovskaya**, Vice President, Biology,  
**The Medicines Company**

4.00 Collaborative development of novel drugs to prevent infection

EUROPEAN VIEW

- Development of clinical stage assets through collaborative ventures
- Progression of XF-73, an alternative to traditional antibiotics
- Preventing infection and addressing resistance

**Ian Hayter**, Projects Director, **Destiny Pharma Ltd**

4.40 Chairman's Closing Remarks and Close of Day Two

Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711


### Official media partners:



### Official Publications



### Supported by



Want to know how you can get involved? Interested in promoting your services to this market?  
Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email: [t.ari@smi-online.co.uk](mailto:t.ari@smi-online.co.uk)